Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
2.190
-0.030 (-1.35%)
At close: Jan 21, 2025, 4:00 PM
2.280
+0.090 (4.11%)
After-hours: Jan 21, 2025, 5:13 PM EST
Autolus Therapeutics Employees
As of December 31, 2023, Autolus Therapeutics had 471 total employees, including 463 full-time and 8 part-time employees. The number of employees increased by 67 or 16.58% compared to the previous year.
Employees
471
Change (1Y)
67
Growth (1Y)
16.58%
Revenue / Employee
$21,425
Profits / Employee
-$573,730
Market Cap
582.81M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
AUTL News
- 4 days ago - Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings - GlobeNewsWire
- 6 weeks ago - Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market - Seeking Alpha
- 2 months ago - Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) - GlobeNewsWire
- 3 months ago - Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - GlobeNewsWire
- 4 months ago - Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case - Seeking Alpha
- 5 months ago - Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript - Seeking Alpha